cousin dupree schreef op 15 januari 2018 09:45:
Zacks Investment Research lowered shares of Pharming Group (OTCMKTS:PHGUF) from a hold rating to a sell rating in a report issued on Wednesday.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
www.thelincolnianonline.com/2018/01/1...